Predictive value of the Seattle Heart Failure Model in patients undergoing left ventricular assist device placement

Journal of Heart and Lung Transplantation

Volumn 29, Issue 9, 2010, Pages 1021-1025

  Ketchum, Eric S ^a   Moorman, Alec J ^a   Fishbein, Daniel P ^a   Mokadam, Nahush A ^a   Verrier, Edward D ^a   Aldea, Gabriel S ^a   Andrus, Shauna ^a   Kenyon, Kenneth W ^a   Levy, Wayne C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Heart failure; Prognosis; Seattle Heart Failure Model; Transplant; Ventricular assist devices

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; BRAIN NATRIURETIC PEPTIDE; CREATININE;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; DIURETIC THERAPY; FEMALE; HEART FAILURE; HOSPITAL DISCHARGE; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SEATTLE HEART FAILURE MODEL; SURVIVAL RATE; SURVIVAL TIME; BLOOD; HEART ASSIST DEVICE; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; STATISTICS; TIME; UNITED STATES; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; BLOOD UREA NITROGEN; CREATININE; FEMALE; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; STROKE VOLUME; SURVIVAL RATE; TIME FACTORS; WASHINGTON;

EID: 79952114286     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2010.05.002     Document Type: Article

References (20)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:480-6.
2. Taylor DO, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report - 2008. J Heart Lung Transplant 2008;27:943-56.
3. Aaronson KD, Eppinger MJ, Dyke DB, et al. Left ventricular assist device therapy improves utilization of donor hearts. J Am Coll Cardiol 2002;39:1247-54. (Pubitemid 34297861)
4. Holman WL, Kormos RL, Naftel DC, et al. Predictors of death and transplant in patients with a mechanical circulatory support device: a multi-institutional study. J Heart Lung Transplant 2009;28:44-50.
5. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-90.
6. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006;113: 1424-33. (Pubitemid 43739439)
7. May HT, Horne BD, Levy WC, et al. Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. Am J Cardiol 2007;100:697-700. (Pubitemid 47223146)
8. Giamouzis G, Kalogeropoulos AP, Georgiopoulou VV, et al. Incremental value of renal function in risk prediction with the Seattle Heart Failure Model. Am Heart J 2009;157:299-305.
9. Kalogeropoulos AP, Georgiopoulou VV, Giamouzis G, et al. Utility of the Seattle Heart Failure Model in patients with advanced heart failure. J Am Coll Cardiol 2009;53:334-42.
10. Levy WC, Mozaffarian D, Linker DT, et al. Can the Seattle Heart Failure Model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy? J Heart Lung Transplant 2009; 28:231-6.
11. Levy W, Lee K, Hellkamp A, et al. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation 2009;120:835-42.
12. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001; 345:1435-43.
13. Park SJ, Tector A, Piccioni W, et al. Left ventricular assist devices as destination therapy: a new look at survival. J Thorac Cardiovasc Surg 2005;129:9-17. (Pubitemid 40038090)
14. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009;361:2241-51.
15. Kirklin JK, Naftel DC, Kormos RL, et al. Second INTERMACS annual report: more than 1,000 primary left ventricular assist device implants. J Heart Lung Transplant 2010;29:1-10.
16. Alba AC, Rao V, Ivanov J, et al. Usefulness of the INTERMACS scale to predict outcomes after mechanical assist device implantation. J Heart Lung Transplant 2009;28:827-33.
17. Schaffer JM, Allen JG, Weiss ES, et al. Evaluation of risk indices in continuous-flow left ventricular assist device patients. Ann Thorac Surg 2009;88:1889-96.
18. Vongooru H, Basraon J, Agnihotri A, et al. Survival estimation by Seattle Heart Failure Model and Heart Failure Survival Score in patients undergoing elective left ventricular assist device placement. J Card Failure 2009;15(suppl):S54.
19. Strueber M, Birks E, Jansz P, et al. Clinical results of the International HeartWare LVAS Bridge to Transplant Trial. J Heart Lung Transplant 2009;28(suppl 1):S255.
20. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007; 357:885-96. (Pubitemid 47347322)